chloropyramine has been researched along with Breast Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hiscox, S; Jones, S; Kandil, S; Prencipe, F; Westwell, AD | 1 |
| Bolderson, E; Burgess, JT; Cuff, K; Lakhani, SR; McNicol, AM; O'Byrne, KJ; Reid, LE; Richard, DJ; Richard, K; Saunus, JM; Zhang, SD | 1 |
| Cance, WG; He, D; Hunt, DL; Kurenova, EV; Magis, AT; Ostrov, DA | 1 |
3 other study(ies) available for chloropyramine and Breast Cancer
| Article | Year |
|---|---|
The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer.
Topics: Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Design; Ethylenediamines; Female; Focal Adhesion Kinase 1; Half-Life; Humans; Microsomes, Liver; Molecular Docking Simulation; Protein Structure, Tertiary | 2018 |
SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer.
Topics: Adult; Aged; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ethylenediamines; Female; Gene Expression; Humans; Middle Aged; Neoplasm Grading; Prognosis; Proportional Hazards Models; Tumor Burden; Tumor Suppressor Proteins | 2016 |
Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo.
Topics: Animals; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Ethylenediamines; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Mice; Phosphorylation; Vascular Endothelial Growth Factor Receptor-3 | 2009 |